63514-63-6

Basic information

• Product Name: N-[4-(2-bromopropanoyl)phenyl]acetamide
• Synonyms: N-[4-(2-bromopropanoyl)phenyl]acetamide
• CAS NO: 63514-63-6
• Molecular Formula: C₁₁H₁₂BrNO₂
• Molecular Weight: 270.12248
• Mol File: 63514-63-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 128-130 °C(Solv: ethanol (64-17-5))
• Boiling Point: 431.6°C at 760 mmHg
• Flash Point: 214.8°C
• Appearance: /
• Density: 1.467g/cm³
• Vapor Pressure: 1.19E-07mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.47±0.70(Predicted)
• CAS DataBase Reference: N-[4-(2-bromopropanoyl)phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(2-bromopropanoyl)phenyl]acetamide(63514-63-6)
• EPA Substance Registry System: N-[4-(2-bromopropanoyl)phenyl]acetamide(63514-63-6)

Safety Data

• Hazardous Substances Data: 63514-63-6(Hazardous Substances Data)

Usage

General Description

N-[4-(2-bromopropanoyl)phenyl]acetamide is a chemical compound that contains a phenyl group substituted with a 2-bromopropanoyl moiety and an acetamide functional group. It is commonly used as a reagent in organic synthesis and pharmaceutical research. The presence of the 2-bromopropanoyl group makes the compound reactive towards various nucleophiles, making it a useful intermediate in the preparation of other organic compounds. The acetamide functional group also imparts some level of hydrolytic stability to the molecule, allowing it to be utilized in various synthetic pathways without undergoing undesired side reactions. Overall, N-[4-(2-bromopropanoyl)phenyl]acetamide is an important chemical building block with a wide range of potential applications in the field of chemistry.

InChI:InChI=1/C11H12BrNO2/c1-7(12)11(15)9-3-5-10(6-4-9)13-8(2)14/h3-7H,1-2H3,(H,13,14)

Upstream product

• 103-84-4 Acetanilid 
• 7148-74-5 2-Bromopropionyl chloride 
• 62-53-3 aniline 
• 70-69-9 1-(4-aminophenyl)-1-propanone 
• 16960-49-9 N-(4-propionylphenyl)acetamide 
• 563-76-8 α-bromopropionyl bromide 

Downstream Products

• 1037019-96-7 C₂₃H₂₈N₂O₂ 
• 104657-22-9 (+/-)-2-(N-tert-butylamino)-4'-aminopropiophenone 
• 97110-67-3 1-(4-acetylaminophenyl)-2-tert.-butylaminopropanone 
• 136609-85-3 6-(3,4-diaminophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one 
• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 36725-28-7 OR-1855 
• 1221499-65-5 (R)-(-)-6-[4-(2-furanylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-63-3 (R)-(-)-6-[4-(2-pyridinylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-62-2 C₁₈H₁₅Cl₂N₃O 
• 1221499-61-1 C₂₁H₂₃N₃O₄ 
• 1221499-60-0 C₁₈H₁₆ClN₃O 
• 1221499-59-7 C₁₈H₁₇N₃O₂ 
• 1221499-58-6 C₁₈H₁₇N₃O₂ 
• 1221499-57-5 C₁₈H₁₇N₃O₃ 

Relevant articles and documents

Optimizing Water Exchange Rates and Rotational Mobility for High-Relaxivity of a Novel Gd-DO3A Derivative Complex Conjugated to Inulin as Macromolecular Contrast Agents for MRI

Thanks to the understanding of the relationships between the residence lifetime τM of the coordinated water molecules to macrocyclic Gd-complexes and the rotational mobility τR of these structures, and according to the theory for paramagnetic relaxation, it is now possible to design macromolecular contrast agents with enhanced relaxivities by optimizing these two parameters through ligand structural modification. We succeeded in accelerating the water exchange rate by inducing steric compression around the water binding site, and by removing the amide function from the DOTA-AA ligand [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(p-aminoanilide)] (L) previously designed. This new ligand 10[2(1-oxo-1-p-propylthioureidophenylpropyl]-1,4,7,10-tetraazacyclodecane-1,4,7-tetraacetic acid (L1) was then covalently conjugated to API [O-(aminopropyl)inulin] to get the complex API-(GdL1)x with intent to slow down the rotational correlation time (τR) of the macromolecular complex. The evaluation of the longitudinal relaxivity at different magnetic fields and the study of the 17O-NMR at variable temperature of the low-molecular-weight compound (GdL1) showed a slight decrease of the τM value (τM310 =?331?ns vs. τM310 =?450?ns for the GdL complex). Consequently to the increase of the size of the API-(GdL1)x complex, the rotational correlation time becomes about 360 times longer compared to the monomeric GdL1 complex (τR?=?33,700?ps), which results in an enhanced proton relaxivity.

(±)-2-(N-tert-Butylamino)-3′-[125I]-iodo-4′- azidopropiophenone: A dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban)

Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4′-position of the aromatic ring. Analog (±)-3 (SADU-3-72) demonstrated modest DAT and α4β2 nAChR affinity. A radioiodinated version was shown to bind covalently to hDAT expressed in cultured cells and affinity-purified, lipid-reincorporated human α4β2 neuronal nAChRs. Co-incubation of (±)-[125I]-3 with non-radioactive (±)-bupropion or (-)-cocaine blocked labeling of these proteins. Compound (±)-[125I]-3 represents the first successful example of a DAT and nAChR photoaffinity ligand based on the bupropion scaffold. Such ligands are expected to assist in mapping bupropion-binding pockets within plasma membrane monoamine transporters and ligand-gated nAChR ion channels.

Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof

The invention relates to a substituted phenylpiperazine aryl alkanol derivative represented by the following general formula and its salt and hydrate, wherein C1 and C2 represent chiral carbon atoms, and the compound is one of the six isomers: (1RS, 2SR), (1RS, 2RS), (1R, 2S), (1S, 2S), (1R, 2R) or (1S, 2R); and R, R1, R2, R3 and Ar are as defined in the specification. The derivative is non-opioid analgesic, has good analgesic effect and relatively small side effects. The invention also relates to a composition comprising the derivative and its use.